Healthcare Equipment and Supplies
Company Overview of Integrated Diagnostics Inc.
Integrated Diagnostics Inc. engages in developing and creating laboratory-developed blood-based molecular diagnostics tools that assist physicians with the early diagnosis of complex diseases with a non-invasive blood test, such as lung cancer by simultaneously monitoring disease molecular markers. It offers Xpresys Lung, a molecular blood test to provide non-invasive objective information for the assessment of pulmonary nodules. Integrated Diagnostics Inc. has a strategic partnership with Agilent Technologies Inc. The company was formerly known as Homestead Clinical Corporation. Integrated Diagnostics Inc. was founded in 2005 and is based in Seattle, Washington.
219 Terry Avenue North
Seattle, WA 98109-5208
Founded in 2005
Key Executives for Integrated Diagnostics Inc.
Chief Executive Officer and Board Member
Co- Founder, President and Chief Scientific Officer
Co-Founder and Scientific Advisor
Co-Founder and Board Member
Compensation as of Fiscal Year 2016.
Integrated Diagnostics Inc. Key Developments
Integrated Diagnostics Inc. Wins $2 Million Federal Contract
May 24 16
Integrated Diagnostics Inc., Seattle, announced that it has won a $2 million federal contract from the U.S. Department of Veterans Affairs National Acquisition Center for medical laboratory testing and analysis services.
Integrated Diagnostics Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:00 PM
Mar 31 15
Integrated Diagnostics Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 03:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Albert A. Luderer, Chief Executive Officer and Board Member.
Caprion Announces Agreement to In-License Xpresys Lung from Indi for Canadian Commercialization
Feb 3 15
Caprion announced an exclusive agreement to in-license Xpresys Lung in Canada from Indi (Integrated Diagnostics). Xpresys Lung is a breakthrough, molecular diagnostic blood test that assists with the management of indeterminate lung nodules. The clinical laboratory developed test is currently only available in the United States and provides physicians with objective information to identify nodules with a high probability of being benign potentially reducing unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system. The agreement marks the continuation of a long-standing collaboration between Indi and Caprion, which began with Caprion as an early partner of Indi in the proteomics clinical discovery of Xpresys Lung. Caprion will hold the exclusive rights to market and commercialize Xpresys Lung in Canada, beginning with Quebec. Caprion will pay Indi royalties and several milestone payments. Exact financial terms of the agreement were not disclosed. Caprion has received support for its Canadian Xpresys Lung commercial efforts from the Government of Quebec as part of the Personalised Medicine Partnership for Cancer (PMPC), a public-private partnership led by Caprion and focused on clinical biomarkers and personalised healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Quebec.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries